Trials / Completed
CompletedNCT03836092
ECGI in Patients With Persistent Atrial Fibrillation
Identification of AF Triggers, Initiators and Perpetuators by Electro Cardio-Graphic Imaging (ECGI) in Patients With Persistent Atrial Fibrillation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- Pacific Rim Electrophysiology Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
To determine the values and limitations of ECGI in guiding ablation and risk stratification in patients with persistent atrial fibrillation.
Detailed description
The patient population will include symptomatic persistent AF patients (N=50). The total of fifty patients will be studied to determine: * The values and limitations of ECGI in identifying atrial fibrillation (AF) triggers, AF initiators and AF perpetuators as targets sites for catheter ablations in patients with persistent AF. * The mechanisms of residual atrial tachycardia/flutter (Res-AT/AFl) after AF substrate ablations by targeting complex fractionated atrial electrograms (CFAE). * If there is a relationship between primary CFAE sites and driver sites or other distinct patterns from the ECGI mapping system. * The rate of AF termination to sinus rhythm after ablation at target sites identified by ECGI
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Radiofrequency ablation | RF applications were delivered with a maximal temperature of 43°C at the catheter tip (SmartTouch Navistar Thermocool catheter) and at the power between 25-50 watts. The primary end points during RF ablation were either complete elimination of areas with CFAE or conversion of AF to normal sinus rhythm (SR). When areas with CFAE were completely eliminated but the atrial arrhythmias persisted (organized atrial flutter or atrial tachycardia), they were subsequently mapped and ablated (occasionally in conjunction with ibutilide, 1 - 2 mgs intravenously over 10 minutes). |
Timeline
- Start date
- 2018-02-23
- Primary completion
- 2022-01-01
- Completion
- 2022-04-01
- First posted
- 2019-02-11
- Last updated
- 2022-04-12
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT03836092. Inclusion in this directory is not an endorsement.